-+ 0.00%
-+ 0.00%
-+ 0.00%

Agios, Avanmzanite Sign Agreement For Pan-European Partnership For PYRUKYND Launch

Benzinga·06/09/2025 12:44:47
Listen to the news
  • PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with PK deficiency
  • The agreement includes commercialization and distribution rights for potential future indications
  • Furthered by this partnership with Agios, Avanzanite is setting a new paradigm in biotech commercial and distribution partnerships, and in how orphan medicines reach patients across Europe